{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:26:47Z","timestamp":1793896007570,"version":"4.8.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402285"],"award-info":[{"award-number":["82402285"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82572256"],"award-info":[{"award-number":["82572256"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202175"],"award-info":[{"award-number":["82202175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2023NSCQ-BHX0012"],"award-info":[{"award-number":["CSTB2023NSCQ-BHX0012"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2025NSCQ-GPX1132"],"award-info":[{"award-number":["CSTB2025NSCQ-GPX1132"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2024NSCQ-KJFZMSX0005"],"award-info":[{"award-number":["CSTB2024NSCQ-KJFZMSX0005"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jconrel.2026.115086","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:25:43Z","timestamp":1780961143000},"page":"115086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ultrasound-activated biomimetic nanobubbles achieve synergistic immunotherapy by tumor cell membrane-based vaccination and PD-L1 PROTAC degradation"],"prefix":"10.1016","volume":"396","author":[{"given":"Yi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115086_bb0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115086_bb0015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115086_bb0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115086_bb0025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/0008-5472.CAN-24-0565","article-title":"Personalized cancer vaccines directed against tumor mutations: building evidence from mice to humans","volume":"84","author":"Fritsch","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115086_bb0035","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","article-title":"NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines","volume":"175","author":"van Montfoort","year":"2018","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.jconrel.2026.115086_bb0040","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-15-0244","article-title":"Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade","volume":"21","author":"Taube","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115086_bb0045","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI98047","article-title":"PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115086_bb0050","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115086_bb0055","first-page":"681","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","volume":"1","author":"Oh","year":"2020","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0060","article-title":"Lymph node and tumor-associated PD-L1(+) macrophages antagonize dendritic cell vaccines by suppressing CD8(+) T cells","volume":"5","author":"Sprooten","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115086_bb0065","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s40425-019-0705-y","article-title":"Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy","volume":"7","author":"Liu","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0075","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1186\/s12967-024-05503-1","article-title":"Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115086_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009905","article-title":"N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer","volume":"12","author":"He","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115086_bb0085","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.apsb.2020.11.001","article-title":"Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo","volume":"11","author":"Luo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0095","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1038\/s41467-025-60107-7","article-title":"Linker-free PROTACs efficiently induce the degradation of oncoproteins","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.jconrel.2026.115086_bb0100","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1039\/D5SC07400B","article-title":"Unveiling BCL-xL-specific PROTAC efficiency and dissociation pathways using native mass spectrometry","volume":"17","author":"Gadallah","year":"2026","journal-title":"Chem. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115086_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020411","article-title":"Cancer-specific delivery of proteolysis-targeting chimeras (PROTACs) and their application to cancer immunotherapy","volume":"15","author":"Moon","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115086_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/jmcb\/mjaf027","article-title":"Targeting the ubiquitin-proteasome system and drug therapy in colorectal cancer","volume":"17","author":"Su","year":"2026","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115086_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115861","article-title":"Self-assembled Nano-PROTACs: bridging chemical design and biological barriers in targeted protein degradation","volume":"234","author":"Zhang","year":"2026","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115086_bb0120","first-page":"1","article-title":"Smart dental materials for antimicrobial applications","volume":"24","author":"Montoya","year":"2023","journal-title":"Bioact. Mater."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115086_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16050674","article-title":"Novel drug delivery systems: an important direction for drug innovation research and development","volume":"16","author":"Chen","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115086_bb0130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2018.06.008","article-title":"Combination of chemotherapy and photodynamic therapy for cancer treatment with sonoporation effects","volume":"283","author":"Lee","year":"2018","journal-title":"J. Control. Release"},{"issue":"22","key":"10.1016\/j.jconrel.2026.115086_bb0135","article-title":"Targeted STING activation using modified ultrasound-responsive microbubbles enhances immune checkpoint blockade against melanoma","volume":"12","author":"Khorsandi","year":"2025","journal-title":"Adv. Sci."},{"issue":"44","key":"10.1016\/j.jconrel.2026.115086_bb0140","doi-asserted-by":"crossref","first-page":"78153","DOI":"10.18632\/oncotarget.18155","article-title":"Nanobubbles as ultrasound contrast agent for facilitating small cell lung cancer imaging","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2026.115086_bb0145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2024.01.028","article-title":"Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - direct comparison of doxorubicin-loaded nanobubbles and microbubbles","volume":"367","author":"Nittayacharn","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115086_bb0150","doi-asserted-by":"crossref","first-page":"0015","DOI":"10.34133\/bmr.0015","article-title":"Nanodrug delivery systems in antitumor immunotherapy","volume":"28","author":"Guo","year":"2024","journal-title":"Biomater. Res."},{"issue":"23","key":"10.1016\/j.jconrel.2026.115086_bb0155","article-title":"Volumetric nanodroplet-enhanced ultrasound surgery combined with immune checkpoint inhibition as a cancer therapy platform","volume":"21","author":"Glickstein","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.115086_bb0160","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2147\/IJN.S451179","article-title":"Targeted ultrasound nanobubbles therapy for prostate cancer via immuno-sonodynamic effect","volume":"19","author":"Huang","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115086_bb0165","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.7150\/thno.41228","article-title":"Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy","volume":"10","author":"Xu","year":"2020","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115086_bb0170","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17425247.2025.2505044","article-title":"Progress and potential of nanobubbles for ultrasound-mediated drug delivery","volume":"22","author":"Chen","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115086_bb0175","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jconrel.2024.04.001","article-title":"Enhanced capillary delivery with nanobubble-mediated blood-brain barrier opening and advanced high resolution vascular segmentation","volume":"369","author":"Gattegno","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115086_bb0180","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.2147\/IJN.S112951","article-title":"Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles","volume":"11","author":"Fan","year":"2016","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115086_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030208","article-title":"Theoretical and experimental gas volume quantification of micro- and nanobubble ultrasound contrast agents","volume":"12","author":"Abenojar","year":"2020","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115086_bb0190","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00262-004-0560-6","article-title":"A listing of human tumor antigens recognized by T cells: march 2004 update","volume":"54","author":"Novellino","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"issue":"43","key":"10.1016\/j.jconrel.2026.115086_bb0195","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.1002\/adma.201602173","article-title":"Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors","volume":"28","author":"Sun","year":"2016","journal-title":"Adv. Mater."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115086_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/biom14101212","article-title":"Homologous targeting effect of cancer cell-derived liposomes (memposomes) mediated by cell adhesion molecules: role of E-cadherin","volume":"14","author":"Cheung","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2026.115086_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216128","article-title":"PROTACs: novel tools for improving immunotherapy in cancer","volume":"560","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115086_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202208553","article-title":"Checkpoint nano-PROTACs for activatable cancer photo-immunotherapy","volume":"35","author":"Zhang","year":"2023","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0215","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115086_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112377","article-title":"Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1","volume":"199","author":"Cheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"534","key":"10.1016\/j.jconrel.2026.115086_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115086_bb0230","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006714","article-title":"Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity","volume":"11","author":"Fernandez-Rodriguez","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"issue":"7670","key":"10.1016\/j.jconrel.2026.115086_bb0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115086_bb0245","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/s41418-023-01219-9","article-title":"USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1","volume":"30","author":"Kuang","year":"2023","journal-title":"Cell Death Differ."},{"issue":"13","key":"10.1016\/j.jconrel.2026.115086_bb0250","doi-asserted-by":"crossref","first-page":"9413","DOI":"10.1021\/acsnano.3c11023","article-title":"Bioorthogonal\/ultrasound activated oncolytic pyroptosis amplifies in situ tumor vaccination for boosting antitumor immunity","volume":"18","author":"Xu","year":"2024","journal-title":"ACS Nano"},{"issue":"6754","key":"10.1016\/j.jconrel.2026.115086_bb0255","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0260","first-page":"5","article-title":"Intranasal circRNA vaccine elicits localized and safer antitumor immunity","volume":"6","author":"Jiang","year":"2026","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.jconrel.2026.115086_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105068","article-title":"The role of therapeutic cancer vaccines in the modern immunotherapy era: state of the art with recent progress and future challenges","volume":"217","author":"Rota","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115086_bb0270","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3340\/jkns.2022.0267","article-title":"Advanced T and natural killer cell therapy for glioblastoma","volume":"66","author":"Yoon","year":"2023","journal-title":"J. Korean Neurosurg. Soc."},{"issue":"13","key":"10.1016\/j.jconrel.2026.115086_bb0275","doi-asserted-by":"crossref","first-page":"eaeb5894","DOI":"10.1126\/sciadv.aeb5894","article-title":"Cold atmospheric plasma-engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity","volume":"12","author":"Li","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115086_bb0280","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4939-2703-6_13","article-title":"Cell fusion between dendritic cells and whole tumor cells","volume":"1313","author":"Koido","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"27","key":"10.1016\/j.jconrel.2026.115086_bb0285","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1021\/acs.nanolett.4c01534","article-title":"Biomimetic ghost nanomedicine-based optotheranostics for cancer","volume":"24","author":"Prasad","year":"2024","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0290","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2521392","article-title":"Cancer cells accelerate exhaustion of persistently activated mouse CD4(+) T cells","volume":"14","author":"Stachowiak","year":"2025","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115086_bb0295","article-title":"Self-assembled peptide-derived proteolysis-ttargeting chimera (PROTAC) nanoparticles for tumor-targeted and durable PD-L1 degradation in cancer immunotherapy","volume":"64","author":"Moon","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115086_bb0300","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02483-2","article-title":"Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression","volume":"41","author":"Wang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115086_bb0305","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-022-05375-7","article-title":"High-potency PD-1\/PD-L1 degradation induced by peptide-PROTAC in human cancer cells","volume":"13","author":"Dai","year":"2022","journal-title":"Cell Death Dis."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592600489X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592600489X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:54:47Z","timestamp":1793894087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592600489X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":61,"alternative-id":["S016836592600489X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115086","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultrasound-activated biomimetic nanobubbles achieve synergistic immunotherapy by tumor cell membrane-based vaccination and PD-L1 PROTAC degradation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115086"}}